HER2 Overexpression Correlates with Survival After Curative Resection of Pancreatic Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2009 May 13

PMID 19432892

Citations 63

Authors

Masahiro Komoto

Bunzo Nakata

Ryosuke Amano

Nobuya Yamada

Masakazu Yashiro

Masaichi Ohira

Kenichi Wakasa

Kosei Hirakawa

Affiliations

Soon will be listed here.

Abstract

HER2 overexpression has been linked to clinical outcomes in several solid tumors, such as breast cancer. However, the correlation between HER2 overexpression and survival in pancreatic carcinoma remains unclear. The impact of HER2 overexpression on survival in pancreatic ductal cancer was examined. Immunohistochemical staining of 129 pancreatic cancers without hematogenous metastases or peritoneal dissemination treated by macroscopically curative resection were analyzed in association with survival data. To determine HER2 overexpression in this pancreatic cancer series, the polyclonal antibody included in HercepTest, which is used worldwide for clinical examination of HER2 overexpression in breast cancer, was used. Immunoreactivity was classified according to the scale presented in the HercepTest Scoring Guidelines. Twenty-two cases (17.1%) had a score of 0, 28 cases (21.7%) had of a score of 1+, 41 cases (31.8%) had a score of 2+, and 38 cases (29.4%) had a score of 3+. Therefore, HER2 overexpression (score 2+ or 3+) was observed in 79 cases (61.2%). Patients with HER2 overexpression tumors had significantly shorter survival times than those with HER2 normal expression (score 0 or 1+) tumors (median survival time, 14.7 vs 20.7 months, respectively; P = 0.0078 on the log-rank test). On multivariate survival analysis, HER2 overexpression remained an independent prognostic factor (hazard ratio, 1.806; P = 0.0258). A significant percentage of pancreatic cancers were demonstrated to have HER2 overexpression, and overexpression of this tyrosine kinase receptor proved to be an independent factor for a worse prognosis. These results should encourage further investigation of treatments using new molecular targeting agents against HER2 protein to improve the survival of pancreatic cancer patients.

Citing Articles

Current and future immunotherapeutic approaches in pancreatic cancer treatment.

Farhangnia P, Khorramdelazad H, Nickho H, Delbandi A J Hematol Oncol. 2024; 17(1):40.

PMID: 38835055 PMC: 11151541. DOI: 10.1186/s13045-024-01561-6.

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.

Bulle A, Liu P, Seehra K, Bansod S, Chen Y, Zahra K Nat Commun. 2024; 15(1):2503.

PMID: 38509064 PMC: 10954758. DOI: 10.1038/s41467-024-46811-w.

Evaluation of HER2Neu Status in Periampullary Cancers in Tertiary Care Centre in Northern India: A Three-Year Retrospective Study.

Qayoom S, Agarwal A, Agarwal P, Anand A, Raj R, Gupta S Cureus. 2023; 15(10):e46646.

PMID: 37937013 PMC: 10627433. DOI: 10.7759/cureus.46646.

An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.

Liu S, Hu Q, Xie Z, Chen S, Li Y, Quan N J Cancer Res Clin Oncol. 2023; 149(17):15589-15608.

PMID: 37653101 PMC: 10620278. DOI: 10.1007/s00432-023-05312-x.

The Mutation Portraits of Oncogenes and Tumor Supressor Genes in Predicting the Overall Survival in Pancreatic Cancer: A Bayesian Network Meta-Analysis.

Aryanti C, Uwuratuw J, Labeda I, Raharjo W, Lusikooy R, Rauf M Asian Pac J Cancer Prev. 2023; 24(8):2895-2902.

PMID: 37642079 PMC: 10685232. DOI: 10.31557/APJCP.2023.24.8.2895.

References

Day J, DiGiuseppe J, Yeo C, Anderson S, Goodman S, Kern S . Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol. 1996; 27(2):119-24. DOI: 10.1016/s0046-8177(96)90364-0. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11):1160-74. DOI: 10.1056/NEJMra0707704. View

Albertson D, Collins C, McCormick F, Gray J . Chromosome aberrations in solid tumors. Nat Genet. 2003; 34(4):369-76. DOI: 10.1038/ng1215. View

Mass R, Press M, Anderson S, Cobleigh M, Vogel C, Dybdal N . Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005; 6(3):240-6. DOI: 10.3816/CBC.2005.n.026. View

Lei S, Appert H, Nakata B, Domenico D, Kim K, Howard J . Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol. 1995; 17(1):15-21. DOI: 10.1007/BF02788354. View

Petit A, Rak J, Hung M, Rockwell P, Goldstein N, Fendly B . Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy.... Am J Pathol. 1997; 151(6):1523-30. PMC: 1858348. View

Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733-43. DOI: 10.1056/NEJMoa064320. View

Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T . Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res. 2006; 12(16):4925-32. DOI: 10.1158/1078-0432.CCR-06-0544. View

10.

Edgerton S, Moore 2nd D, Merkel D, Thor A . erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol. 2003; 11(3):214-21. DOI: 10.1097/00129039-200309000-00003. View

11.

Jaehne J, Urmacher C, Thaler H, Cordon-Cardo C, Meyer H . Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol. 1992; 118(6):474-9. DOI: 10.1007/BF01629433. View

12.

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

13.

Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R . Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res. 2002; 22(3):1593-7. View

14.

Stoecklein N, Luebke A, Erbersdobler A, Knoefel W, Schraut W, Verde P . Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol. 2004; 22(23):4737-45. DOI: 10.1200/JCO.2004.05.142. View

15.

Yamanaka Y, Friess H, Kobrin M, Buchler M, Kunz J, Beger H . Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol. 1993; 24(10):1127-34. DOI: 10.1016/0046-8177(93)90194-l. View

16.

Huang S, Harari P . Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 2000; 17(3):259-69. DOI: 10.1023/a:1006384521198. View

17.

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

18.

Safran H, Iannitti D, Ramanathan R, Schwartz J, Steinhoff M, Nauman C . Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004; 22(5):706-12. DOI: 10.1081/cnv-200032974. View

19.

Kern J, Schwartz D, Nordberg J, Weiner D, Greene M, Torney L . p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990; 50(16):5184-7. View

20.

Rusnak D, Lackey K, Affleck K, Wood E, Alligood K, Rhodes N . The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2002; 1(2):85-94. View